Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EBIT (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed EBIT for 12 consecutive years, with -$24.7 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT fell 73.85% year-over-year to -$24.7 million; the TTM value through Mar 2026 reached -$163.1 million, down 325.63%, while the annual FY2025 figure was -$152.6 million, 281.2% down from the prior year.
  • EBIT hit -$24.7 million in Q1 2026 for Crescent Biopharma, up from -$91.5 million in the prior quarter.
  • Across five years, EBIT topped out at -$2.6 million in Q3 2024 and bottomed at -$91.5 million in Q4 2025.
  • Average EBIT over 5 years is -$18.0 million, with a median of -$11.0 million recorded in 2023.
  • Year-over-year, EBIT surged 73.19% in 2024 and then tumbled 883.85% in 2025.
  • Crescent Biopharma's EBIT stood at -$10.6 million in 2022, then grew by 9.71% to -$9.6 million in 2023, then skyrocketed by 72.57% to -$2.6 million in 2024, then plummeted by 3377.46% to -$91.5 million in 2025, then surged by 72.97% to -$24.7 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$24.7 million, -$91.5 million, and -$25.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.